Combination drug treatment before bladder cancer surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You cannot take the standard chemotherapy (cisplatin) because of kidney problems, hearing loss, nerve damage, or other reasons, or you choose not to.
- Your bladder cancer has not spread beyond the bladder and you are able to have surgery (removal of the bladder).
- Your tumor has a certain level of a protein called HER2 (at least 1+ on testing).
- You are willing to use effective birth control during the study (if you or your partner could become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial tests a combination of two drugs (Tislelizumab and Palbociclib) given before bladder removal surgery. It is for people with bladder cancer that has a specific genetic change and who cannot take the standard chemotherapy cisplatin.
This trial studies a combination of two drugs for bladder cancer that has not spread beyond the bladder. It aims to help patients who want to avoid bladder removal surgery, potentially preserving their bladder.
This study tests a combination of two drugs given directly into the bladder for a type of early-stage bladder cancer that has a specific protein marker called HER2. The goal is to see if the combination helps prevent the cancer from coming back.
This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.